Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseActive, not recruitingPhase 22026-02-27NCT03589222

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
PETHEMA Foundation21

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Clinica Universitaria de NavarraPamplonaSpain4
Hospital 12 de OctubreMadridSpain13
Hospital Central de AsturiasOviedoSpain4
Hospital Clinic de BarcelonaBarcelonaSpain31
Hospital Clinico de MadridMadridSpain1
Hospital Clinico Universitario de SalamancaSalamancaSpain7
Hospital Dr PesetValenciaSpain3
Hospital Germans Trials i PujolBadalonaSpain2
Hospital ICO de GironaGironaSpain1
Hospital ICO de L'hospitaletL'Hospitalet de LlobregatSpain1
Hospital Morales MeseguerMurciaSpain2
Hospital Universitario de CanariasSanta Cruz de TenerifeSpain11
Hospital Universitario de DonostiaSan SebastiánSpain5
Hospital Universitario de SantiagoSantiago de CompostelaSpain1
Hospital Virgen Del RocioSevilleSpain9